Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas

BACKGROUND: Activation of the mammalian target of rapamycin (mTOR) signaling pathway is thought to be a key driver of tumor growth in Merlin (NF2)-deficient tumors. Everolimus is an oral inhibitor of mTOR complex 1 (mTORC1) with antitumor activity in a variety of cancers. METHODS: We conducted a sin...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Karajannis, Matthias A., Legault, Geneviève, Hagiwara, Mari, Giancotti, Filippo G., Filatov, Alexander, Derman, Anna, Hochman, Tsivia, Goldberg, Judith D., Vega, Emilio, Wisoff, Jeffrey H., Golfinos, John G., Merkelson, Amanda, Roland, J. Thomas, Allen, Jeffrey C.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2014
Témata:
Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3895376/
https://ncbi.nlm.nih.gov/pubmed/24311643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not150
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky